News and Press Releases
Optibrium Appoints James Halle as chief commercial officer
Key appointment brings extensive software commercial experience to drive global growth 16 July 2024 – Cambridge, UK – Optibrium, a leading developer of software and AI solutions for drug discovery...
Category: Drug Discovery
Posted: July 16, 2024
Optibrium Ltd. 7221 Cambridge Research Park, Beach Drive, Cambridge, CB25 9TL, UK
Signant Health Appoints 20-Year Life Sciences Veteran Paul Richmond to executive leadership team as chief commercial officer
15 July 2024 – Pennsylvania, US – Signant Health, the leader in evidence generation for modern clinical trials, announced today the appointment of Paul Richmond as chief commercial officer. A...
Category: Clinical Trials, Other, Pharmaceutical
Posted: July 16, 2024
Mogrify appoints Dr Jonathan Appleby as chief scientific officer
Strategic hire bolsters executive leadership team as company progresses multiple therapeutic programmes toward and into clinical development 15 July 2024 – Cambridge, UK – Mogrify, a regenerative medicine company developing...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: July 15, 2024
Pistoia Alliance Research Finds 77% of Researchers Not Using In Vitro Alternatives to Animal Testing, as it Launches Non-Animal Models Community
Alliance calls on experts to join its new collaborative community, seeking to overcome regulatory and data challenges preventing the replacement and reduction of animal testing 11 July 2024 -- Boston,...
Category: Biotechnology, Drug Discovery, Pharmaceutical
Posted: July 11, 2024
Pan Cancer T secures €4.25m in Seed Extension Round to advance next-generation T cell therapies
July 11 2024, Rotterdam, the Netherlands – Pan Cancer T B.V., a pioneering biotech start-up developing next-generation T cell therapies for solid cancer treatment, has successfully closed a €4.25m Seed...
Category: Drug Delivery
Posted: July 11, 2024
Concr launches trial using digital twins for outcome prediction in breast cancer
10 July 2024, London United Kingdom – Concr announces that first patients have been recruited to the VISION trial, an observational clinical study evaluating Concr’s therapeutic response predictive algorithm defining...
Category: Biotechnology
Posted: July 10, 2024
Pascal Piedbois MD PhD joins One2Treat as chief medical officer to advance patient-centric innovation in clinical trial design and market access
One2Treat reflects patient priorities in a single multi-facet treatment assessment, reducing trial sample size and accelerating patient access to new treatments. 9 July 2024 -- Brussels, Belgium -- In this...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: July 10, 2024
Epsilogen announces CTA approval for phase 1b trial of MOv18 IgE in platinum-resistant ovarian cancer
Phase 1b study expected to initiate in H2 2024 Previously reported phase 1 results showed MOv18 IgE to be safe and well-tolerated, with evidence of anti-tumour activity. 8 July 2024...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: July 8, 2024
Stockholm 3 commercially available in the US
A3P Biomedical AB, a leading Swedish diagnostics company specializing in advanced prostate cancer diagnostics, and BioAgilytix, a global bioanalytical services provider, are excited to announce that Stockholm3 for early detection...
Category: Biotechnology
Posted: July 3, 2024
Clinigen appoints Fernando Ballester as Chief Financial Officer
2 July 2024 -- London, UK -- Clinigen, the global pharmaceutical services company, today announces the appointment of Fernando Ballester as chief financial officer (CFO), effective 1 August 2024. Fernando,...
Category: Other, Pharmaceutical
Posted: July 2, 2024
RYBREVANT (amivantamab) in combination with chemotherapy is the first therapy approved by the European Commission for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations
Approval is supported by the phase 3 PAPILLON study, which showed amivantamab plus chemotherapy significantly reduced the risk of disease progression or death by 60% compared to chemotherapy alone 28...
Category: Clinical Trials, Pharmaceutical
Posted: June 28, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
CHMP adopts positive opinion for BALVERSA (erdafitinib) for the treatment of adult patients with unresectable or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations
Pending approval, erdafitinib would become the first therapy targeting FGFR3 alterations in patients with metastatic urothelial carcinoma, one of Europe’s most common cancers The CHMP’s recommendation is based on results...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 28, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
CN Bio appoints Lydia Seymour as VP People and Culture to further strengthen leadership team
Key appointment to support continued UK and US team expansion 27 June 2024 -- Cambridge, UK -- CN Bio, a leading provider of single- and multi-organ microphysiological systems, today announced...
Category: Biotechnology, Other, Pharmaceutical
Posted: June 27, 2024
Prevention and early detection of gastrointestinal cancers take on new importance amidst a younger population
Emerging research on early-onset gastrointestinal cancers highlights need for better prevention, diagnosis and treatment Less invasive, smart technologies could improve participation in and efficacy of GI cancer screening Studies presented...
Category: Other
Posted: June 27, 2024
Avallano Strengthens Leadership with New Chief Strategy Officer to Drive AI-Powered Clinical Research Innovation
26 June 2024 -- South Carolina, US -- Avallano, an AI-enabled clinical research company, today announced the appointment of Michael A Ibara PharmD, as chief strategy officer (CSO). Dr Ibara...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 26, 2024
